S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

CEL-SCI Stock Forecast, Price & News

-0.29 (-2.37 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range N/A
52-Week Range
Volume362,884 shs
Average Volume1.36 million shs
Market Capitalization$514.18 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CEL-SCI logo


CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.


September 21, 2021 |  americanbankingnews.com
CEL-SCI Shares Spike To Session Highs; Up 7%
CEL-SCI Shares Spike To Session Highs; Up 7%
September 18, 2021 |  benzinga.com
September 7, 2021 |  americanbankingnews.com
CEL-SCI (NYSEAMERICAN:CVM) Stock Price Down 5.7%
CEL-SCI (NYSEAMERICAN:CVM) Stock Price Down 5.7%
September 3, 2021 |  americanbankingnews.com
CVM: Primum Non Nocere - Yahoo Finance
CVM: Primum Non Nocere - Yahoo Finance
August 25, 2021 |  finance.yahoo.com
CVM: Primum Non Nocere
CVM: Primum Non Nocere
August 25, 2021 |  finance.yahoo.com
CEL-SCIs Tough Road Ahead - Seeking Alpha
CEL-SCI's Tough Road Ahead - Seeking Alpha
August 20, 2021 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.34 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

What stocks does MarketBeat like better than CEL-SCI?

Wall Street analysts have given CEL-SCI a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CEL-SCI wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Wednesday, December 29th 2021.
View our earnings forecast for CEL-SCI

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) issued its quarterly earnings data on Monday, August, 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.12.
View CEL-SCI's earnings history

How has CEL-SCI's stock price been impacted by COVID-19?

CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CVM stock has increased by 22.7% and is now trading at $11.95.
View which stocks have been most impacted by COVID-19

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

Shares of CEL-SCI reverse split before market open on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:
  • Geert R. Kersten, CEO, Chief Financial Officer, Treasurer & Director
  • Patricia B. Prichep, Secretary & Senior Vice President-Operations
  • Eyal Talor, Chief Scientific Officer
  • William Jones, Vice President-Quality Assurance
  • Daniel H. Zimmerman, Senior VP-Research & Cellular Immunology

What other stocks do shareholders of CEL-SCI own?

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.58%), State Street Corp (6.55%), Vanguard Group Inc. (4.84%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Bank of America Corp DE (0.00%). Company insiders that own CEL-SCI stock include Geert R Kersten, John Cipriano, Patricia B Prichep, Peter R Young and Robert Eugene Watson.
View institutional ownership trends for CEL-SCI

Which major investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including Mangrove Partners, Citadel Advisors LLC, Walleye Trading LLC, Commonwealth Equity Services LLC, Western Standard LLC, Susquehanna International Group LLP, Goldman Sachs Group Inc., and Rafferty Asset Management LLC.
View insider buying and selling activity for CEL-SCI
or view top insider-selling stocks.

Which major investors are buying CEL-SCI stock?

CVM stock was bought by a variety of institutional investors in the last quarter, including Group One Trading L.P., BlackRock Inc., Simplex Trading LLC, Vanguard Group Inc., Cutler Group LP, JPMorgan Chase & Co., Natixis, and Schonfeld Strategic Advisors LLC. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Patricia B Prichep, Peter R Young, and Robert Eugene Watson.
View insider buying and selling activity for CEL-SCI
or or view top insider-buying stocks.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $11.95.

How much money does CEL-SCI make?

CEL-SCI has a market capitalization of $514.18 million and generates $560,000.00 in revenue each year. The company earns $-30,250,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does CEL-SCI have?

CEL-SCI employs 2,020 workers across the globe.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

Where are CEL-SCI's headquarters?

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at (703) 506-9460 or via email at [email protected].

This page was last updated on 9/26/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.